Our Story

Cascade Prodrug is dedicated on furthering the development of its proprietary hypoxia-activated switch technology to improve the therapeutic options for patients with solid tumor indications

Within the United States, roughly 35% of cancer patients will be diagnosed with a solid tumor cancer. There are dozens of solid tumor cancers that are difficult to treat- prostate, cervical, pancreatic, non-small cell lung cancer, and head & neck cancers. To date, conventional chemotherapies have been unable to effectively treat these cancers.

The primary reason for the limited success of traditional therapies for solid tumors is due to the complex solid tumor microenvironment. As solid tumors grow, they develop abnormal vasculatures characterized by low oxygen levels and a lack of nutrients. These slow growing cell populations are hallmarks of solid tumors and are both difficult to reach and difficult to kill by current standards of care.

Cascade Prodrug’s novel chemotherapy approach has been designed to take advantage of one of the well-characterized features of solid tumors tissue—tumor hypoxia. Our proprietary hypoxia-activated prodrug technology provides the foundation for a significantly improved chemotherapy option for treating solid tumors—Cascade Prodrug’s Chemotherapy Trifecta™ Solution.

Our Technology

Cascade Prodrug employs a platform technology that has lead to our lead compound, CPD100.  CPD100 is a proprietary N-oxide prodrug of vinblastine, an approved cytotoxic vinca-alkaloid that is used clinically to treat several hematologic malignancies. CPD100 is stable at normal tissue O2 levels but ‘switches’ to cytotoxic vinblastine under hypoxic conditions. By creating a novel on-off switch for vinblastine, we take advantage of tumor hypoxia and trigger drug conversion in the tumor where it’s needed, thus limiting the exposure of healthy tissue to a potent cytotoxic agent. Cascade Prodrug believes that this technology will significantly increase the maximum-tolerated-dose of chemotherapy, thereby improving outcomes in patients with solid tumors.

Our studies have demonstrated that tumor cells grown in tissue culture are 25-times more susceptible to killing by CPD100 when they are incubated under hypoxic conditions.